Webinar

Contents

Chair

Prof. Ralf Weiskirchen

The head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy, and Clinical Chemistry (IFMPEGKC) at the RWTH University Hospital Aachen, Germany

Scientific Secretariat

Prof. Amedeo Lonardo

Editor-in-Chief of Metabolism and Target Organ Damage

Moderator

Assoc. Prof. Gyorgy Baffy

  • Department of Medicine, VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  • Associate Professor of Medicine at Harvard Medical School and Chief of Gastroenterology at the VA Boston Healthcare System, Boston, MA, USA

Speaker(s)

Prof. Wolfgang Stremmel

Medical Center Baden-Baden, Baden-Baden, Germany

Dr. Mohamad Jamalinia

Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Iran

Prof. Alessandro Mantovani

Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

Dr. Shelley Keating

School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia

Asst. Prof. Thomas Jensen

  • University of Colorado Department of Medicine, Division of Endocrinology, Denver, CO, USA
  • Director of Diabetes and Metabolic Medicine for Transplant and Co-Director of NAFLD Multidisciplinary Clinics
Programme
Programme
Time (GMT-2, Germany)Chair/Moderator/SpeakersTopic
04:00 PM - 04:10 PMRalf WeiskirchenIntroduction: etiology, burden and clinical spectrum of liver fibrosis
Session 1 – Pathobiology and diagnosis
04:10 PM - 04:25 PMWolfgang StremmelLow phosphatidylcholine in biliary mucus as pathogenetic factor in primary sclerosing cholangitis (PSC), the genuine fibrotic disease of the biliary tract?
Session 2 – Clinical spectrum
04:25 PM - 04:40 PMMohamad JamaliniaImpact of Liver Fibrosis on Cardiovascular Risk: Prognostic Insights and Limitations
04:40 PM - 04:55 PMAlessandro MantovaniRole of Liver Fibrosis in the Progression of Chronic Kidney Disease
Session 3 – Management options
04:55 PM - 05:10 PMShelley KeatingExercise for Fibrosis/Fibroinflammation in MASLD
05:10 PM - 05:25 PMThomas JensenDrug treatment of liver fibrosis
Session 4 – Presentation of the Journal, general discussion, and concluding remarks
05:25 PM - 05:35 PMGyorgy BaffyPresentation of M&TOD
05:35 PM - 05:50 PMGyorgy BaffyQ&A
05:50 PM - 06:00 PMRalf WeiskirchenConcluding remarks

Relevant Special Issue(s)

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

https://www.oaepublish.com/specials/mtod.2034

Moments

Presentation

NaN

NaN

NaN

NaN

NaN

NaN

NaN

NaN
Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/